Cheng Chen
Senior Medical Director, Clinical Lead for KRAS G12C Program D3 Bio
Seminars
Thursday 18th September 2025
Phase I/II Study of D3S-001, a New Generation KRAS G12C Inhibitor in Advanced/ Metastatic Solid Tumors with KRAS G12C Mutations
2:00 pm
- Favorable Safety Profile: No dose-limiting toxicities (DLTs) or treatment-related deaths were observed. Grade 3 treatment-related adverse events (TRAEs) occurred in about 15% of patients (no Grade 4 or 5), and no discontinuations due to toxicity
- Promising Early Efficacy: D3S-001 demonstrated strong and consistent anti-tumor activity (confirmed ORR 73.5%) across all KRAS G12C-mutated cancers; in addition, promising activities observed in G12Ci refractory NSCLC patients; and in patients with CNS metastases
- Rapid and early ctDNA clearance and positive correlation with clinical responses, supporting novel G12C target inhibition MoA
